Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
GYRE has been in the news recently: GYRE THERAPEUTICS is not specifically mentioned in the provided information, but it is part of the broader biopharmaceutical landscape alongside companies like IDEAYA Biosciences, which received FDA Breakthrough Therapy designation for darovasertib targeting uveal melanoma. Additionally, Neurocrine Biosciences reported that all patients treated with their medication INGREZZA® reached a therapeutic dose from the start, highlighting advancements in treatment efficacy.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
